Alzamend Neuro Correlations
ALZN Stock | USD 1.29 0.02 1.53% |
The current 90-days correlation between Alzamend Neuro and TRACON Pharmaceuticals is -0.07 (i.e., Good diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Alzamend Neuro Correlation With Market
Good diversification
The correlation between Alzamend Neuro and DJI is -0.04 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Alzamend Neuro and DJI in the same portfolio, assuming nothing else is changed.
Alzamend |
Moving together with Alzamend Stock
0.8 | FDMT | 4D Molecular Therapeutics | PairCorr |
0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.69 | INKT | Mink Therapeutics | PairCorr |
0.74 | MREO | Mereo BioPharma Group | PairCorr |
0.79 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
0.64 | PEPG | PepGen | PairCorr |
0.72 | PIRS | Pieris Pharmaceuticals | PairCorr |
0.69 | ACRV | Acrivon Therapeutics, | PairCorr |
0.9 | ADAP | Adaptimmune Therapeutics | PairCorr |
0.72 | AFMD | Affimed NV | PairCorr |
0.65 | STOK | Stoke Therapeutics | PairCorr |
0.88 | BDTX | Black Diamond Therap | PairCorr |
Moving against Alzamend Stock
0.75 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.57 | NAMS | NewAmsterdam Pharma | PairCorr |
0.46 | MNOV | MediciNova | PairCorr |
0.45 | PHVS | Pharvaris BV | PairCorr |
0.43 | OPT | Opthea | PairCorr |
0.75 | CRVS | Corvus Pharmaceuticals | PairCorr |
0.66 | AVTE | Aerovate Therapeutics | PairCorr |
0.57 | SGMO | Sangamo Therapeutics Buyout Trend | PairCorr |
0.51 | VREX | Varex Imaging Corp | PairCorr |
0.49 | ABEO | Abeona Therapeutics | PairCorr |
0.43 | AGIO | Agios Pharm | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Alzamend Stock performing well and Alzamend Neuro Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alzamend Neuro's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
TCON | 6.84 | (2.12) | 0.00 | (0.82) | 0.00 | 19.59 | 52.05 | |||
SLDB | 3.53 | (0.97) | 0.00 | (0.24) | 0.00 | 7.44 | 24.49 | |||
KZR | 3.04 | 0.16 | 0.05 | 0.27 | 3.00 | 4.93 | 51.13 | |||
SNTI | 3.18 | (0.33) | 0.00 | (1.95) | 0.00 | 7.04 | 29.17 | |||
XFOR | 4.97 | (0.74) | 0.00 | (0.36) | 0.00 | 6.90 | 62.35 | |||
INZY | 2.72 | (1.26) | 0.00 | (0.60) | 0.00 | 5.07 | 16.62 | |||
TERN | 3.32 | (0.54) | 0.00 | (0.37) | 0.00 | 5.68 | 34.09 | |||
DAWN | 2.07 | (0.17) | 0.00 | (0.09) | 0.00 | 3.84 | 11.44 | |||
HOOK | 2.83 | (1.35) | 0.00 | (1.09) | 0.00 | 6.51 | 22.98 |
Alzamend Neuro Corporate Management
Henry Esq | General VP | Profile | |
Kenneth CPA | Senior Finance | Profile | |
David Katzoff | Chief Officer | Profile | |
Stephan Jackman | CEO Director | Profile |